Granted Patent
B2
US 12,311,022 · App. 19/003,301 · Granted May 27, 2025
Bispecific chimeric antigen receptors targeting CD20 and BCMA
Inventors:
Yihong Yao (Rockville, MD); Jiaqi Huang (Rockville, MD); Shigui Zhu (Rockville, MD); Xin Yao (Rockville, MD); Xiaobing Luo (Rockville, MD); Yutian Wei (Rockville, MD)
Assignee:
ABELZETA INC.
A61K40/31A61K35/17A61K40/11A61K40/4221A61K40/4224A61P37/02C07K16/2878C07K16/2887C12N5/0636A61K2239/13A61K2239/21A61K2239/22A61K2239/29C07K2317/622C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Claims (6)
1. A bispecific chimeric antigen receptor (CAR), comprising an anti-CD20 antigen-binding region and an anti-BCMA antigen-binding region, wherein the bispecific CAR comprises the amino acid sequence set forth in SEQ ID NO:26.
2. An immune cell comprising the bispecific CAR of claim 1 .
3. The immune cell of claim 2 , wherein the immune cell is a T cell or a natural killer (NK) cell.
4. A nucleic acid sequence encoding the bispecific CAR of claim 1 .
5. A vector comprising the nucleic acid sequence of claim 4 .
6. A pharmaceutical composition, comprising the immune cell of claim 2 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 27, 2024
From: YAO, YIHONG; HUANG, JIAQI; ZHU, SHIGUI; YAO, XIN; LUO, XIAOBING; WEI, YUTIAN
To: ABELZETA INC.
Reel/Frame 069689/0312 →
Continuity (4)
Continuation
PCTUS2024022317
· Mar 29, 2024
Provisional Application
63493495
· Mar 31, 2023
Provisional Application
63509371
· Jun 21, 2023
References Cited (269)
US 5350674A
· Boenisch et al.
· 1994
[cited by applicant]
US 5399346A
· Anderson et al.
· 1995
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5585362A
· Wilson et al.
· 1996
[cited by applicant]
US 5589466A
· Felgner et al.
· 1996
[cited by applicant]
US 6074841A
· Gearing et al.
· 2000
[cited by applicant]
US 6326193B1
· Liu et al.
· 2001
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7462352B2
· Hansen et al.
· 2008
[cited by applicant]
US 8287864B2
· Goldenberg et al.
· 2012
[cited by applicant]
US 8329181B2
· Martin et al.
· 2012
[cited by applicant]
US 8529902B2
· Teeling et al.
· 2013
[cited by applicant]
US 8906682B2
· June et al.
· 2014
[cited by applicant]
US 8911993B2
· June et al.
· 2014
[cited by applicant]
US 8916381B1
· June et al.
· 2014
[cited by applicant]
US 8975071B1
· June et al.
· 2015
[cited by applicant]
US 9101584B2
· June et al.
· 2015
[cited by applicant]
US 9102760B2
· June et al.
· 2015
[cited by applicant]
US 9102761B2
· June et al.
· 2015
[cited by applicant]
US 9150664B2
· Kufer
· 2015
[cited by applicant]
US 9328156B2
· June et al.
· 2016
[cited by applicant]
US 9447194B2
· Jensen
· 2016
[cited by applicant]
US 9464140B2
· June et al.
· 2016
[cited by applicant]
US 9481728B2
· June et al.
· 2016
[cited by applicant]
US 9499629B2
· June et al.
· 2016
[cited by applicant]
US 9518123B2
· June et al.
· 2016
[cited by applicant]
US 9540445B2
· June et al.
· 2017
[cited by applicant]
US 9598500B2
· Kufer
· 2017
[cited by applicant]
US 9662354B2
· Hyde et al.
· 2017
[cited by applicant]
US 9834590B2
· Campana et al.
· 2017
[cited by applicant]
US 9919061B2
· McDonagh et al.
· 2018
[cited by applicant]
US 20090148447A1
· Ledbetter
· 2009
[cited by applicant]
US 20110091473A1
· Golab et al.
· 2011
[cited by applicant]
US 20130004480A1
· Parren
· 2013
[cited by applicant]
US 20140093454A1
· Teeling et al.
· 2014
[cited by applicant]
US 20140105915A1
· Algate
· 2014
[cited by applicant]
US 20140154253A1
· Ng
· 2014
[cited by applicant]
US 20160333108A1
· Forman et al.
· 2016
[cited by applicant]
US 20170226216A1
· Morgan
· 2017
[cited by applicant]
US 20180044415A1
· Escarpe
· 2018
[cited by applicant]
US 20180118823A1
· Thompson et al.
· 2018
[cited by applicant]
US 20180258391A1
· June et al.
· 2018
[cited by applicant]
US 20180355318A1
· Delaney et al.
· 2018
[cited by applicant]
US 20190112380A1
· Chaudhary
· 2019
[cited by applicant]
US 20200040096A1
· Forman et al.
· 2020
[cited by applicant]
US 20200093861A1
· Klein et al.
· 2020
[cited by applicant]
US 20200306375A1
· Lobb et al.
· 2020
[cited by applicant]
US 20200371091A1
· Pruteanu-Malinici
· 2020
[cited by examiner]
US 20230104705A1
· Yao et al.
· 2023
[cited by applicant]
US 20230212255A1
· Yao et al.
· 2023
[cited by applicant]
US 20230242613A1
· Yao et al.
· 2023
[cited by applicant]
US 20240000839A1
· Yao
· 2024
[cited by examiner]
US 20240115605A1
· Yao et al.
· 2024
[cited by applicant]
US 20240139243A1
· Yao et al.
· 2024
[cited by applicant]
CN 101544694A
· 2009
[cited by applicant]
CN 103562225A
· 2014
[cited by applicant]
CN 104114578A
· 2014
[cited by applicant]
CN 104379179A
· 2015
[cited by applicant]
CN 105384825A
· 2016
[cited by applicant]
CN 106795217A
· 2017
[cited by applicant]
CN 107827989A
· 2018
[cited by applicant]
CN 109423495A
· 2019
[cited by applicant]
CN 109575143A
· 2019
[cited by applicant]
CN 110606893A
· 2019
[cited by applicant]
CN 112390891A
· 2021
[cited by applicant]
CN 112608387A
· 2021
[cited by applicant]
JP 2014520088A
· 2014
[cited by applicant]
JP 2014534242A
· 2014
[cited by applicant]
JP 2015504306A
· 2015
[cited by applicant]
JP 2015092865A
· 2015
[cited by applicant]
JP 2017513478A
· 2017
[cited by applicant]
JP 2017522882A
· 2017
[cited by applicant]
JP 2017538710A
· 2017
[cited by applicant]
JP 2018508215A
· 2018
[cited by applicant]
KR 1020140105757A
· 2014
[cited by applicant]
WO 0023573A2
· 2000
[cited by applicant]
WO 0129058A1
· 2001
[cited by applicant]
WO 0196584A2
· 2001
[cited by applicant]
WO 2012088461A2
· 2012
[cited by applicant]
WO 2012163805A1
· 2012
[cited by applicant]
WO 2013072406A1
· 2013
[cited by applicant]
WO 2013123061A1
· 2013
[cited by applicant]
WO 2016014576A1
· 2016
[cited by applicant]
WO 2016014789A2
· 2016
[cited by applicant]
WO 2016097231A2
· 2016
[cited by applicant]
WO 2016139487A1
· 2016
[cited by applicant]
WO 2016166521A1
· 2016
[cited by applicant]
WO 2016166630A1
· 2016
[cited by applicant]
WO 2016179319A1
· 2016
[cited by applicant]
WO 2017025038A1
· 2017
[cited by applicant]
WO 2017072716A1
· 2017
[cited by applicant]
WO 2017172981A2
· 2017
[cited by applicant]
WO 2017210617A2
· 2017
[cited by applicant]
WO 2017211900A1
· 2017
[cited by applicant]
WO 2018028647A1
· 2018
[cited by applicant]
WO 2018145649A1
· 2018
[cited by applicant]
WO 2019126724A1
· 2019
[cited by applicant]
WO 2019128952A1
· 2019
[cited by applicant]
WO 2019129177A1
· 2019
[cited by applicant]
WO 2019196713A1
· 2019
[cited by applicant]
WO 2019232503A1
· 2019
[cited by applicant]
WO 2020010235A1
· 2020
[cited by applicant]
WO 2020025596A1
· 2020
[cited by applicant]
WO 2020061796A1
· 2020
[cited by applicant]
WO 2020072536A1
· 2020
[cited by applicant]
WO 2020151752A1
· 2020
[cited by applicant]
WO 2021184673A1
· 2021
[cited by applicant]
WO 2022119923A1
· 2022
[cited by applicant]
WO 2022164886A2
· 2022
[cited by applicant]
U.S. Appl. No. 19/005,160, filed Dec. 30, 2024.
[cited by applicant]
U.S. Appl. No. 19/006,633, filed Dec. 31, 2024.
[cited by applicant]
Ataca et al. “Chimeric Antigen Receptor T Cell Therapy in Hematology”, Turk J Hematol 2015; 32:285-294. [10 pages].
[cited by applicant]
Belovezhec. Design and Comparative Analysis of CD20-Specific Chimeric Antigen Receptors. Proceedings of XIV International Conference of Students, Graduate Students and Young Scientists “Perspectives in Fundamental Scien…
[cited by applicant]
Berahovich et al. “CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth”, Cancers, vol. 10, No. 9, 2018:323 [16 pages].
[cited by applicant]
Bernabei et al. “PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells”, Blood, vol. 132 (Supplement 1), Nov. 29, 2018 (Nov. 29…
[cited by applicant]
Bhoj et al. “Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy”, Blood 128, 360-370 (2016) [12 pages].
[cited by applicant]
Budde et al. “Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma”, PLoS One, vol. 8, No. 12, 2013, pp. 1…
[cited by applicant]
Cao et al. “Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma”, (2019) Medicine 98: 42(e17506) [8 pages].
[cited by applicant]
Casan et al. “Anti-CD20 monoclonal antibodies: reviewing a revolution”, (2018) Human Vaccines & Immunotherapeutics 14(12): 2820-2841. [23 pages].
[cited by applicant]
Chow et al. “Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CART-cell therapy”, (2019) Am. J. Hematol. 94(8): E209-E213. [7 pages].
[cited by applicant]
Chuda et al. “Ofatumumab: A Novel Anti-CD20Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia”, Current Drug Therapy, 2012, 7, 281-289. [9 pages].
[cited by applicant]
Dogan et al. “B-cell maturation antigen expression across hematologic cancers: a systematic literature review”, Blood Cancer J. 10, 73 (2020) [13 pages].
[cited by applicant]
Dondelinger et al. “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition”, Front Immunol, Oct. 2018; 9:2278. [15 pages].
[cited by applicant]
Dotti et al., Design and development of therapies using chimeric antigen receptor-expressing T cells, Immunol Rev. 2014, 257(1):107-126 [35 pages].
[cited by applicant]
Du et al. “Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20”, Mol Immunol. 2009; 46(11-12):2419-23.
[cited by applicant]
Feng et al. “Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma”, Scandinavian Journal of Immunology, vol. 92, No. 2, 2020, pp. 109-119. [11 pages].
[cited by applicant]
Fesnak et al., Engineered T Cells: The Promise and Challenges of Cancer Immunotherapy, Nature Reviews Cancer, vol. 16, No. 9, 2016, pp. 566-581 (in 2 parts).
[cited by applicant]
Gen Bank Accession AA022134.1 (2005) [2 pages].
[cited by applicant]
GenBank Accession No. AKH40187, Version AKH40187.1, GenBank, Jul. 28, 2015. [4 pages].
[cited by applicant]
Ghafouri et al. “CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas”, Cancer Res., Jul. 1, 2021; 81(13):Abstract CT007. [5 pages].
[cited by applicant]
Hallek. “Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment”, (2017) Am J Hematol. 92: 946-965. [20 pages].
[cited by applicant]
Hamdy et al. “Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells”, (2005) J. Immunol. …
[cited by applicant]
Hao et al. “A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice”, Blood, 2011; 118 (5):1294-304 [11 pages].
[cited by applicant]
International Search Report and Written Opinion of PCT/US2024/022317, mailed Jul. 30, 2024. [10 pages].
[cited by applicant]
International Search Report and Written Opinion of PCT/CN2019/081064, mailed Jul. 3, 2019. [18 pages].
[cited by applicant]
International Search Report and Written Opinion of PCT/US21/61410, mailed Mar. 30, 2022. [11 pages].
[cited by applicant]
International Search Report and Written Opinion of PCT/CN2018/075867, mailed May 9, 2018.
[cited by applicant]
International Search Report and Written Opinion of PCT/US22/13875, mailed Jul. 8, 2022 [10 pages].
[cited by applicant]
Jabbour et al. “Monoclonal antibodies in acute lymphoblastic leukemia”, Blood 2015; 125(26): 4010-4016. [7 pages].
[cited by applicant]
Jenks et al. “Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus”, Immunity 49, 725-739 e726 (2018) [35 pages].
[cited by applicant]
Jensen et al. “Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells”, Immunol Rev. (2014) 257(1):127 [32 pages].
[cited by applicant]
Jonnalagadda et al. “Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy”, Molecular Therapy 2015; vol. 23 No. 4, 757-768. [12 pages].
[cited by applicant]
Korycka-Wolowiec et al. “Ofatumumabfor treating chronic lymphocytic leukemia: a safety profile”, Expert Opinion on Drug Safety 2015; 14(12): 1945-1959. [15 pages].
[cited by applicant]
Krumbholz et al. “B cells and antibodies in multiple sclerosis pathogenesis and therapy”, Nature reviews Neurology, 2012, 8(11): 613-23. [11 pages].
[cited by applicant]
Ku et al. “Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab”, Blood Reviews, vol. 31, No. 1, 2016, pp. 23-35 [13 pages].
[cited by applicant]
Kunik et al. “Structural consensus among antibodies defines the antigen binding site”, PLoS Comput Biol. 2012; 8(2):e1002388. [12 pages].
[cited by applicant]
Kussie et al. “A single engineered amino acid substitution changes antibody fine specificity”, J. Immunol. 1994; 152(1): 146-52. [7 pages].
[cited by applicant]
Lee et al. “The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer”, Clin. Cancer Res. (2012) 18(10):2780 [19 pages].
[cited by applicant]
Lin. “Ofatumumab: a novel monoclonal anti CD20 antibody”, (2010) Pharmacogenomics and Personalized Medicine 3: 51-59. [9 pages].
[cited by applicant]
Lin et al. “Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma”, Leukemia. 2021, 35(3): 752-76 [21 pages].
[cited by applicant]
Liu et al. “Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from
[cited by applicant]
Lopez-Atalya et al. “Development and Maintenance of the Brain's Immune Toolkit: Microglia and Non-Parenchymal Brain Macrophages”, Dev Neurobiol. 2018; 78(6): 561-579. [19 pages].
[cited by applicant]
Lulla et al. “The Use of Chimeric Antigen Receptor T Cells in Patients with Non-Hodgkin Lymphoma”, (2018) Clinical Advances in Hematology & Oncology, 16(5): 375-386. [21 pages].
[cited by applicant]
Mackensen et al. “Anti-CD19 Car T cell therapy for refractory systemic lupus erythematosus”, Nat. Med. 28, 2124-2132 (2022). [20 pages].
[cited by applicant]
Madduri et al. “Cartitude-1:Phase 1 b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma”, 62nd ASH Annual Meetin…
[cited by applicant]
Mailankody. “Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 Evolve study …
[cited by applicant]
Metelo et al. “Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups”, Blood, vol. 134, 2019: 1834 [3 pages].
[cited by applicant]
Morgan et al. “Unraveling B cell trajectories at single cell resolution”, Trends Immunol. 43, 210-229 (2022) [20 pages].
[cited by applicant]
Munshi et al. “Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results”, Journal of Clinical Oncology, 2020,…
[cited by applicant]
Nakagawa et al. “
[cited by applicant]
NCBI Accession AMZ04820, 2016, 1 page.
[cited by applicant]
NCBI Accession ANS59202, 2016, 1 page.
[cited by applicant]
Panka et al. “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies”, Proc Natl Acad Sci USA 1988; 85(9):3080-4. [5 pages].
[cited by applicant]
Parker et al. “Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies”, Cell. 2020; 183(1):126-142.e17 [35 pages].
[cited by applicant]
Patel et al. “Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus” , (2020) EMJ Hematology, 8(1): 105-12. [8 pages].
[cited by applicant]
Pavlasova et al. “The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy”, Haematologica, 105(6), 1494-1506 (2020). [13 pages].
[cited by applicant]
Pisetsky et al. “New insights into the role of antinuclear antibodies in systemic lupus erythematosus”, Nat. Rev. Rheumatol. 16, 565-579 (2020) [32 pages].
[cited by applicant]
Qin et al. “Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results”, Sig Transduct Target Ther 8, 5 (2023).
[cited by applicant]
Qu et al. “Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/ refractory multiple myeloma”, J Immunother Cancer. 2022; 10(9):e005145 [12 pages].
[cited by applicant]
Ramos et al. “CAR-T Cell Therapy for Lymphoma”, Annu. Rev. Med. 2016; 67: 165-183. [22 pages].
[cited by applicant]
Riaz et al. “Anti-CD19 and anti-CD20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis”, Immunotherapy (2017) 9(12), 979-993. [16 pages].
[cited by applicant]
Rosenberg et al. “Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma”, New Eng. J. of Med. 319: 1676 (1988). [5 pages].
[cited by applicant]
Rubtsov et al. “Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c B-cell population is important for the development of autoimmunity”, Blood, 2011; 118(5):1305-15 [11 pages].
[cited by applicant]
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci USA 1982;79(6): 1979-83. [5 pages].
[cited by applicant]
Rufener et al. “Preserved Activity of CD20-Specific Chimeric Antigen Receptor-A Expressing T Cells in the Presence of Rituximab” , Cancer Immunology Research, 4(6), 2016, pp. 509-519. [12 pages].
[cited by applicant]
Ryan et al. “Antibody targeting of B-cell maturation antigen on malignant plasma cells”, Mol Cancer Ther 2007; 6(11):3009-3018. [11 pages].
[cited by applicant]
Salmon. “Arming T cells against B cells in systemic lupus erythematosus”, Nat. Med. 28, 2009-2010 (2022). [2 pages].
[cited by applicant]
Sela-Culang et al. “The structural basis of antibody-antigen recognition”, Front Immunol. 2013;4:302. [13 pages].
[cited by applicant]
Shah et al. “Bispecific anti-CD20, anti-CD19 CART cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial”, Nat Med. 2020; 26(10):1569-1575. [19 pages].
[cited by applicant]
Sharei et al. “A vector-free microfluidic platform for intracellular delivery”, PNAS (2013) 110(6): 2082-2087 [6 pages].
[cited by applicant]
Shetty et al. “Liver sinusoidal endothelial cells—gatekeepers of hepatic immunity”, Nat Rev Gastroenterol Hepatol. 2018; 15(9): 555-567. [13 pages].
[cited by applicant]
Tai et al. “Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment”, Cancer research. 2006; 66(13):6675-82 [8 pages].
[cited by applicant]
Taubmann et al. “Long term safety and efficacy of CAR-T cell treatment in refractory systemic lupus erythematosus -data from the first seven patients”, Annals of the Rheumatic Diseases, OP0141, p. 93 (2023) [2 pages].
[cited by applicant]
Teeling et al. “The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20”, J Immunol 2006; 177: 362-371. [10 pages].
[cited by applicant]
Teeling et al. “Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas”, (2004) Blood 104: 1793-1800. [8 pages].
[cited by applicant]
Till et al. “Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells”, (2008) Blood112(6): 2261-2271. [11 pages].
[cited by applicant]
Till et al. “CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results”, Blood (2012) 119(17): 3940-3950 [11 pages].
[cited by applicant]
Ui-Tei et al. “Sensitive assay of RNA interference in
[cited by applicant]
Wang et al. “Human autoimmune diseases: a comprehensive update”, J. Intern. Med. 2015, 278(4):369-95 [27 pages].
[cited by applicant]
Wang et al. “IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE”, Nat. Commun. 9, 1758 (2018).
[cited by applicant]
Wark et al. “Latest technologies for the enhancement of antibody affinity”, Adv Drug Deliv Rev. 2006; 58 (5-6):657-70. [14 pages].
[cited by applicant]
Wong et al. “Structural requirements for a specificity switch and for maintenance of affinity using mutational analysis of a phage-displayed anti-arsonate antibody of Fab heavy chain first complementarity-determining re…
[cited by applicant]
Wriggers et al. “Control of Protein Functional Dynamics by Peptide Linkers”, Current Trends in Peptide Science (2005) 80(6): 736-746 [11 pages].
[cited by applicant]
Wu et al. “Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange”, Protein Eng. (2001) 14(12): 1025-1033. [9 pages].
[cited by applicant]
Zhang et al. “Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report”, (2016) Signal Transduction and T…
[cited by applicant]
Zhou et al. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor-T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis', BMC Cancer. 2018; 18(1):929, 13 pages.
[cited by applicant]
Dorner et al. “Mechanisms of B cell autoimmunity in SLE”, Arthritis Res. Ther. 13, 243 (2011) [12 pages].
[cited by applicant]
Lee et al. “B cell depletion therapies in autoimmune disease: advances and mechanistic insights”, Nat. Rev. Drug Discov. 20, 179-199 (2021) [21 pages].
[cited by applicant]
Chavez et al. “CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products”, Ther Adv Hematol. 2019; 10:2040620719841581. [20 pages].
[cited by applicant]
Martyniszyn et al. “CD20-CD19 Bispecific CART Cells for the Treatment of B-Cell Malignancies”, Hum Gene Ther. 2017; 28(12):1147-1157. [11 pages].
[cited by applicant]
Schneider et al. “A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines”, Journal for Immuno Therapy of Cancer. 2017; 5:42. [17 pages].
[cited by applicant]
Tong et al. “Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma”, Blood. 2020; 136(14):1632-1644. [13 pages].
[cited by applicant]
Wang et al. “Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells”, (2014) Clinical Immunology 155: 160-175. …
[cited by applicant]
Watanabe et al. “Target antigen density governs the efficacy of anti-CD20-CD28-CD3ζ chimeric antigen receptor-modified effector CD8+ T cells”, J Immunol. 2015; 194(3):911-20. [10 pages].
[cited by applicant]
Zah et al. “T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells”, Cancer Immunol Res. 2016; 4(6):498-508. [15 pages].
[cited by applicant]
Zah et al. “Addendum: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells”, Cancer Immunol Res. 2016;4(7):639-41. [3 pages].
[cited by applicant]
Zhu et al. “Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center”, Cytotherapy. 2018; 20(3):394-406. [14 pages].
[cited by applicant]
Jensen et al. “CD20 is a molecular target for scFvFc:zeta receptor redirected T-cells: implications for cellular immunotherapy of CD20 malignancy”, (1998) Biology of Blood and Marrow Transplant, 4: 75-83. [9 pages].
[cited by applicant]
Cited By (1)